Brochure | September 23, 2024

Delivery Of mAbs And Other Biologics: VitalDose® EVA Drug Delivery Platform

Source: Celanese
mAbs GettyImages-1441786721

RNA therapeutics hold promise for various diseases, but delivery challenges can arise. VitalDose® EVA provides a solution for controlled and sustained release of RNA therapeutics, including ASOs, siRNA, miRNA, and others. This platform utilizes ethylene vinyl acetate (EVA) copolymer, a bioinert and biocompatible material. Drugs are incorporated into EVA and extruded into implants of desired shapes and sizes.

This brochure takes a look at VitalDose® EVA's advantages. It enables continuous release for extended periods, eliminating the need for frequent injections. The platform's proven biocompatibility and listing on the FDA Inactive Ingredient Database ensure safety. Customizable configurations and release profiles allow for tailored drug delivery. Additionally, VitalDose® EVA is compatible with both ligand-conjugated and non-conjugated RNA molecules.

access the Brochure!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Pharmaceutical Online? Subscribe today.

Subscribe to Pharmaceutical Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Pharmaceutical Online